Inflammation in children with chronic kidney disease linked to gut dysbiosis and metabolite imbalance

Johannes Holle^{1,2,3,*}, Hendrik Bartolomaeus^{2,3,4,5}, Ulrike Löber^{2,3,4,6}, Felix Behrens^{1,3,6,7}, Theda U. P. Bartolomaeus^{2,3,4,6}, Harithaa Anandakumar^{2,4,5}, Moritz I. Wimmer^{2,3,4,5,8}, Dai Long Vu^{4,9}, Mathias Kuhring^{4,6,10}, Andras Maifeld², Sabrina Geisberger^{4,11}, Stefan Kempa^{4,11}, Philip Bufler¹, Uwe Querfeld¹, Stefanie Kitschke¹, Denise Engler¹, Leonard D. Kuhrt^{1,4}, Oliver Drechsel¹², Kai-Uwe Eckardt⁵, Sofia K. Forslund^{2,3,4,6,13}, Andrea Thürmer¹⁴, Victoria McParland^{2,4}, Jennifer A. Kirwan^{4,9}, Nicola Wilck^{2,3,5,6,*}, Dominik Müller^{1,*}

1 1 Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité -
2 Universitätsmedizin Berlin, 13353 Berlin, Germany

3 2 Experimental and Clinical Research Center (ECRC), a cooperation of Charité -
4 Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC), 13125
5 Berlin, Germany

6 3 DZHK (German Centre for Cardiovascular Research), partner site Berlin, 13316 Berlin,
7 Germany.

8 4 Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125
9 Berlin, Germany

10 5 Department of Nephrology and Medical Intensive Care Medicine, Charité -
11 Universitätsmedizin Berlin, 13353 Berlin, Germany

12 6 Charité - Universitätsmedizin Berlin and Berlin Institute of Health, 10117 Berlin, Germany

13 7 Institute of Physiology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany

14 8 Department of Internal Medicine IV, Division of Endocrinology, Diabetology and
15 Nephrology, University Hospital of Tübingen, 72076 Tübingen, Germany

16 9 Berlin Institute of Health Metabolomics Platform, Berlin Institute of Health (BIH), 10178
17 Berlin, Germany

18 10 Core Unit Bioinformatics, Berlin Institute of Health (BIH), 10178 Berlin, Germany

19 11 The Berlin Institute for Medical Systems Biology, 10115 Berlin, Germany

20 12 MF1 Bioinformatics, Robert Koch Institute, 13353 Berlin, Germany

21 13 European Molecular Biology Laboratory, 69117 Heidelberg, Germany

22 14 MF2 Genome Sequencing, Robert Koch Institute, 13353 Berlin, Germany

23 # Authors contributed equally to this publication

24 * corresponding authors

25 **Abstract**

26 Chronic kidney disease (CKD) is characterized by a sustained pro-inflammatory response.
 27 The underlying mechanisms are incompletely understood, but may be linked to gut dysbiosis.
 28 Dysbiosis has been described in adults with CKD; however, comorbidities limit CKD-specific
 29 conclusions. We analyzed the fecal microbiome, metabolites and immune phenotypes in
 30 children at three different CKD stages (G3-G4, G5 (hemodialysis), after kidney
 31 transplantation) and healthy controls. Serum TNF- α and sCD14 were stage-dependently
 32 elevated, indicating inflammation and gut barrier dysfunction. We observed microbiome
 33 alterations in CKD, including a diminished production of short-chain fatty acids. Bacterial
 34 tryptophan metabolites were increased in CKD. CKD serum activated the aryl hydrocarbon
 35 receptor and stimulated TNF- α production by monocytes, corresponding to a shift towards
 36 intermediate/non-classical monocytes. Unsupervised T cell analysis revealed pro-
 37 inflammatory shifts in MAIT and Treg cells. Thus, gut barrier dysfunction and microbial
 38 metabolites exacerbate inflammation and may therefore contribute to the increased
 39 cardiovascular burden in CKD.

40 Introduction

41 Despite ongoing efforts to improve the treatment of patients with chronic kidney disease
42 (CKD), they still suffer from high morbidity and mortality, primarily due to cardiovascular
43 diseases (CVD)¹. Besides known risk factors such as arterial hypertension and proteinuria¹,
44 recent studies suggest a crucial role for microbially produced metabolites in promoting
45 inflammation^{2,3} and, as a consequence, progression of CKD and CVD^{1,3,4}.

46 There is longstanding evidence showing that an imbalance in the bacterial community
47 residing in the gut with changes in its functional composition, termed dysbiosis, is common in
48 adult patients with CKD^{5,6}. Beyond the influence of CKD, a variety of other factors, such
49 influence of diet and drugs, are suspected to contribute to dysbiosis in CKD⁶. These changes
50 are paralleled by an altered bacterial metabolism of nutrients and a systemic accumulation of
51 uremic toxins of bacterial origin, such as indoxyl sulfate (IxS)⁷. It is conceivable that dysbiosis
52 and metabolite dysbalance aggravate systemic inflammation, which could provide a potential
53 mechanism for the high rate of premature cardiovascular events³.

54 Recently, we demonstrated a positive association between IxS and early cardiovascular
55 disease in children with CKD⁸. In contrast to adults with CKD, children are less affected by
56 risk factors such as diabetes, obesity, and metabolic syndrome, but mainly suffer from
57 congenital anomalies of the kidney and urinary tract (CAKUT)⁹. Thus, a pediatric cohort
58 offers the unique opportunity to analyze the impact of CKD on microbiota-host interaction
59 more specifically.

60 Our cohort includes pediatric CKD patients, those on hemodialysis (HD), patients after
61 kidney transplantation (KT) and age-matched healthy controls (HC). We show, for the first
62 time a CKD specific dataset of gut microbiome composition, altered microbial metabolism of
63 nutrients, and the corresponding impact on inflammation and immune cell dysregulation in
64 children suffering from CKD. We connect the bacterial metabolite dysbalance to a pro-
65 inflammatory immune cell signature, emphasizing the importance of the microbiota for
66 chronic inflammation in CKD. The fact that these dysbiosis-driven immunological changes

67 are already detectable in children with CKD highlights the potential of microbiota-targeted
68 therapies to improve prognosis of CKD patients across all ages.

69 Patients and methods

70 Study population

71 In this cross-sectional study, we recruited patients from the Department of Pediatric
72 Gastroenterology, Nephrology, and Metabolic Diseases at Charité University hospital in
73 Berlin, Germany, between February 2018 and June 2018. Written informed consent was
74 obtained from all participants and/or their parents prior to study entry. The study was
75 approved by the local Ethical Review Board (EA2/162/17). All procedures performed were in
76 accordance with the ethical standards of the institutional and national research committees
77 and the 1964 Helsinki declaration and its later amendments or comparable standards.

78 Patients (age 3-18 years) were enrolled in the following groups:

- 79 - CKD group: CKD stage G3-G4, estimated GFR (eGFR) 15-60 ml/min*1.73m²
- 80 - HD group: CKD stage G5D, patients on maintenance hemodialysis, enrolled earliest
81 four weeks after initiation of HD
- 82 - KT group: patients after successful KT, earliest four weeks after KT, without a
83 history of rejection or chronic graft failure, eGFR > 60ml/min*1.73m²
- 84 - HC group: normal kidney function, treated at the hospital for reasons other than
85 kidney disease

86 We excluded patients with a body weight below 15kg, acute or chronic inflammatory
87 diseases, fever, diabetes, chronic liver disease, inflammatory bowel disease, or other
88 gastrointestinal disorders (constipation, diarrhea, short bowel syndrome). Patients with
89 antibiotic prophylaxis or treatment within the four weeks prior to recruitment were excluded.

90 Statistical analysis

91 Microbiome and metabolome analysis: Alpha diversities of microbial communities (Shannon
92 diversity as computed by RTK, defined at the OTU level) were compared between groups
93 using Kruskal-Wallis (KW) test. Beta diversity was assessed using Euclidean (metabolome)

94 and Canberra (microbiome) dissimilarity index between samples computed using vegan
95 package v2.5-7. Principal Coordinates Analysis (PCoA) was performed using the vegan
96 package v2.5-7 (employing Euclidean and Canberra distance metrics as above).
97 PERMANOVA was performed using the adonis function from the vegan package v2.5-7. We
98 estimate differential abundance on phylum and genus level between groups using the
99 package DESeq2 v1.30.1. The DESeq2 pipeline uses negative binomial distribution models
100 to test for differential abundance between testing conditions. We ran the pipeline with
101 normalized counts under default settings. *P* values were adjusted according to Benjamini-
102 Hochberg (BH) false discovery rates (FDR) correction. A q-value of <0.1 was considered
103 statistical significant.

104 For each pair of patient groups, features from the TRP analysis were compared using two-
105 sided Mann-Whitney-U (MWU) tests with effect sizes calculated as Cliff's delta metric per the
106 R ordom package v3.1. Effect sizes were taken as Spearman's rho. All significance
107 estimates were adjusted for multiple tests using BH-FDR correction. To assess the effect of
108 patient groups on tryptophan pathway metabolites (concentrations), multifactor ANOVAs
109 were calculated per metabolite to account for multiple groups as well as potential
110 confounders (including age, sex, ethnical background, underlying disease category, BMI, and
111 eGFR).

112 The co-abundance network of host, microbiome and metabolome features was calculated
113 from the dataset as a whole by assessing pairwise Spearman correlations and adjusted for
114 multiple testing using BH-FDR correction as implemented in the R psych package v1.9.12.
115 Edges for which absolute rho > 0.3 and Q < 0.1 were visualized using the iGraph R package.
116 Correlations were separately also assessed stratifying for group effects using the R coin
117 package v1.3.1.

118 Flow cytometry: For all FlowSOM clusters we computed log2 fold changes (fc). Cluster log2fc
119 were visualized using ggplot2 package v3.3.5. For all subpopulations of Treg and MAIT cells,
120 we calculated log2fc and assessed statistical significance using two-sided MWU-tests

between HD and HC with BH-FDR correction. A q-value of <0.1 was considered statistically significant. Data was visualized using the EnhancedVolcano package v4.1.2.

Boxplots: Analysis and graphical representation was performed in GraphPad Prism 9.3.1 (GraphPad Software, CA, USA). Boxplots depict median and interquartile range with whiskers from min to max. Overlaid data points represent individual patients or measurements. Normality was assessed using Q-Q-plots and Shapiro-Wilk test. For more than two groups we performed one-way ANOVA with Tukey post-hoc test or KW test with Dunn's post-hoc test, as appropriate. For two group comparisons, we performed two-sided Student's t-test or two-sided MWU test, as appropriate.

For all analysis *P* value of <0.05 (unadjusted or adjusted, as appropriate) and a *Q* value of <0.1 was considered statistically significant.

Results

Childhood CKD marked by arterial hypertension, inflammation and leaky gut

Ten healthy individuals (HC) and 38 patients were enrolled in the study (Supplementary Figure 1). Baseline characteristics are given in Table 1. Participant mean age was 10.6 ± 3.8 years with 21 females and 27 males. CAKUT was the most prevalent underlying disease category. Patients treated with HD had a median time on dialysis of six months (range 3 – 29 months) with a median residual diuresis of 50 ml per day (range 0 – 1800 ml per day) and a mean Kt/V of 1.56 ± 0.27 (SD), indicating adequacy of HD treatment. Patients after KT had a stable graft function with a mean eGFR of 78.8 ± 19.4 ml/min*1.73m². The median time from transplantation was 48 months (range 10 – 125 months).

Both the CKD group (CKD stage G3-G4) and the HD group (CKD stage G5D) were hypertensive (83% and 91%, respectively) and received antihypertensive treatment (1.8 ± 1.5 antihypertensive drugs in the CKD group and 2.4 ± 1.9 drugs in the HD group, Figure 1a, Table 1). Six HD patients (55%) exhibited hypertensive blood pressures at the time of study enrolment despite treatment (Table 1). In the HD and CKD groups serum levels of the pro-inflammatory cytokine TNF- α were stage-dependently increased and significantly higher than in the HC group (Figure 1b), while differences in the levels of other pro- and anti-inflammatory cytokines did not reach significance (Supplementary Table 2). Notably, TNF- α was also significantly elevated in patients after KT compared to HC (Figure 1b). We next investigated serum levels of the tight junction protein zonulin-1 (Zo-1) and the lipopolysaccharide (LPS) binding protein soluble CD14 (sCD14), which were elevated in CKD and HD compared to control and KT (Figure 1c), indicating stage-dependent intestinal barrier dysfunction and CKD-associated endotoxemia. Thus, in the absence of classical cardiovascular risk factors other than hypertension, CKD in children is characterized by elevated serum markers of inflammation and leaky gut.

Microbiome alterations in CKD

Since intestinal barrier dysfunction may be associated with dysbiosis, we next sought to analyze the taxonomic composition of the gut microbiome. We performed 16S amplicon sequencing in n=32 study participants with available fecal samples. We observed a high interindividual compositional variability at phylum level (Figure 2a). Microbiome richness and diversity, as measured by the Shannon diversity index, tended to be lower in CKD and HD patients compared to HC but this difference did not reach statistical significance (Figure 2b). However, analysis of beta diversity (Canberra distance) indicated significant differences in microbiome composition between groups, with CKD and HD groups separating most clearly from the HC (Figure 2c, $p = 0.01$). Analysis of bacterial composition on genus level revealed significant alterations predominantly in HD patients (Figure 2d). First, relative abundances of Firmicutes and Actinobacteria such as *Fusicatenibacter* (belonging to the family of Lachnospiraceae), *Subdoligranulum* (Ruminococcaceae), and *Bifidobacterium* (Bifidobacteriaceae) were significantly diminished in HD patients compared to HC. Second, we found an increase in relative abundance of Proteobacteria and Bacteroidetes, such as *Citrobacter* (Enterobacteriaceae), *Parasutterella* (Parasutterellaceae), and several genera of *Bacteroides* (Bacteroidaceae) in CKD and HD groups compared to HC and KT. Taken together, the taxonomic microbiome changes in CKD are stage-dependent, most pronounced in the HD group and less pronounced after KT. The abundance of proteolytic bacteria (such as *Citrobacter*) increases in CKD whereas saccharolytic bacteria (such as *Bifidobacterium*) decrease.

CKD stage-dependent dysbalance of bacterial metabolites

To investigate the functional effects of the observed alterations in microbiome composition on host physiology, we focused a plasma metabolite analysis on tryptophan (TRP) metabolites and SCFA. Dietary TRP is a substrate for both cellular metabolism and bacterial proteolytic fermentation and the latter is a source of microbial produced uremic toxins, such as IxS. We found significant differences in the abundance of TRP metabolites in CKD and HD compared to the HC and KT groups (Figure 3a). CKD and HD patients showed a large-

scale shift from TRP to its indole and kynurenine (KYN) metabolites, which was predominantly driven by an increase of IxS (Figure 3b). We found a significant decrease in plasma TRP concentrations in patients with CKD and HD, while IxS and 5 KYN metabolites (KYN, kynurenic acid (KA), 3-OH-kynurenine (3OH-KYN), anthranilic acid (AA), xanthurenic acid (XA)) were significantly elevated (Figure 3c). Interestingly, patients after KT had similar metabolite levels compared to HC with the exception of KYN and 3OH-KYN (Figure 3c). Individual values of TRP, IxS and, KA are shown across the different groups in Figure 3d-f. The activation of the cellular KYN pathway is also indicated by the ratio of KYN to TRP, which was significantly elevated in CKD and HD (Figure 3g). A multivariate ANOVA showed that age, sex, ethnic background, underlying disease category, and BMI did not confound metabolite levels. Only group and eGFR had an impact on several of the compounds (Supplementary Table 3), confirming their accumulation with declining eGFR. Because indole and KYN metabolites have been shown to activate the aryl hydrocarbon receptor (AhR), a transcription factor and potential mediator of microbiome-host interactions, we measured the AhR activating potential of serum from the HD and HC group *in vitro* using a cell-based reporter assay. Serum from HD patients induced a significantly higher AhR activity as compared to HC (Figure 3h). Similarly, IxS activates the AhR in a dose-dependent manner (Supplementary Figure 2).

To further functionally validate our findings of decreased abundancies of saccharolytic microbes, we measured the abundance of a central enzyme for bacterial SCFA production by qPCR of fecal DNA using degenerate primers. The abundancy of the butyrate gene was lower in the DNA extracted from fecal samples of HD patients relative to the other patient groups (Supplementary Figure 3a). Next, we measured SCFA in serum. The SCFA propionate and isobutyrate were reduced in patients with HD compared to HC, while serum concentrations of butyrate did not differ significantly between groups (Supplementary Figure 3b). Thus, we were able to show on a functional level that the observed stage-dependent microbiome changes have an impact on the production and abundance of bacterial metabolites.

In order to comprehensively visualize the relationship of clinical, microbial and metabolomic parameters, we performed a correlation network analysis (Figure 4). Here, TNF- α correlated positively with sCD14, Proteobacteria, IxS, several KYN metabolites and biomarkers of kidney function (Figure 4a, positive correlations). Conversely, the SCFA propionate and isobutyrate correlated inversely with TNF- α , IxS, KYN metabolites and kidney function (Figure 4b, negative correlations). Firmicutes correlated positively with microbial diversity, butyrate and I3PA. These associations support our assumption of kidney function as a catalyst of gut bacteria-driven inflammation.

Monocyte subsets contribute to the pro-inflammatory phenotype in CKD

The AhR is expressed in various immune cells including myeloid cells and is known to modulate their function¹⁰. It is assumed that the accumulation of AhR ligands in CKD leads to immune cell activation. We therefore isolated monocytes from healthy donors and incubated them with serum from HD patients or HC. Monocytes incubated with HD serum showed a significantly higher TNF- α production (Figure 5a). Similarly, incubation of isolated monocytes with IxS dose-dependently increased TNF- α production which could be reversed by co-incubation with the synthetic AhR-antagonist CH-223191, highlighting the importance of AhR-mediated immune activation in CKD (Figure 5a).

In order to get a broader overview of changes in relevant immune cell populations in CKD, we re-collected peripheral blood mononuclear cells (PBMC) from seven HC and six HD patients for immunophenotyping using flow cytometry. Unsupervised FlowSOM analysis¹¹ of our monocyte and dendritic cell targeting flow panel (see Supplementary table 1, supplementary figure 4, Figure 5b), showed phenotypic alterations of monocytes (cluster 3, Figure 5c) being decreased (Figure 5d) and dendritic cell (cluster 7, Figure 5c) being increased (Figure 5d) in HD patients. Using classical hierarchical gating, we observed similar abundances of total monocytes (identified by HLA-DR, CD14, and CD16 as described in¹²), but a significant shift from classical (CD14+CD16-) towards non-classical (CD14-CD16+) and intermediate (CD14+CD16+) monocytes in HD (Figure 5e), the latter two being known for

their potent production of TNF- α ¹³. Hierarchical gating within the dendritic cell population revealed no significant differences of dendritic cell types (Supplementary Figure 5). Thus, HD patients are characterized by alterations within myeloid cells, showing a shift from classical to pro-inflammatory intermediate and non-classical monocytes.

Pro-inflammatory T cell subsets in CKD

Since SCFA and TRP metabolites are known to modulate T cell differentiation and function, we expanded our flow cytometry to include analysis of T cells (Supplementary table 1, T surface panel, supplementary figure 4). We again performed FlowSOM analysis using 8 clusters (Figure 6a). Mucosal associated invariant T (MAIT) cells and a subpopulation of regulatory T cells (Treg) (Clusters 6 and 3, respectively, Figure 6b) exhibited the largest effects between HD and HC patients (Figure 6c). We confirmed this finding by classical hierarchical gating, with circulating MAIT cells (CD3+CD161+TCRV α 7.2+) being decreased in HD (Supplementary Figure 6a). Next, we performed a more detailed analysis of MAIT cell subpopulations. After adjusting for multiple testing, we found a decrease of CD4-CD8- MAIT cells, while CD4+CD8- and CD4+CD8+ cells were enriched in HD (Figure 6d, f). Moreover, MAIT cells of HD patients displayed an effector memory phenotype (CD45RA-, CD62L-) and expressed more PD-1, indicative of increased activation. Importantly, upon *in vitro* restimulation, MAIT cells of HD patients secreted significantly more interleukin-17A (IL-17A) (Figure 6d, f).

In addition, we identified changes within a CD4+CD25+CD127- cell cluster (Cluster 3, Figure 6a-c), indicating alterations in Treg subpopulations. Total Treg proportions were not altered between HC and HD (Supplementary Figure 6b). However, since different subpopulations with partly different functions are known to exist within the total Treg population, we extended the Treg characterization (Supplementary table 1, T surface and T activation)¹⁴. Adjusted for multiple testing, several Treg subpopulations, characterized by activation markers and chemokine receptors, were significantly changed in HD patients (Figure 6e). In detail, Treg from HD patients with a central-memory phenotype (CD45RA-, CD62L+) showed a higher

267 expression of PD-1 indicating activation state. Based on the expression of chemokine
 268 receptors, Th1-like (CXCR3+), Th17-like (CXCR3-CCR6+CCR4+CCR10-) and Th22-like
 269 (CXCR3-CCR6+CCR4+CCR10+) Treg were significantly diminished in HD patients
 270 compared to HC (Figure 6e, g). Taken together, we observed significant alterations in T cell
 271 subtypes, namely MAIT cells and Treg, which play an important role in mucosal immunity
 272 and inflammation.

Discussion

Inflammation is a hallmark of CKD, detectable even at young age and particularly prognosis-determining. We show in children with CKD, that intestinal barrier dysfunction and dysbiosis are associated with a systemic bacterial metabolite imbalance that contributes to the pro-inflammatory phenotype of several immune cells including monocytes and T cells. We also provide novel insight into the microbiota-immune crosstalk mediated by TRP metabolites and SCFA in CKD. Thus, we demonstrate a stage-dependent aberration of the microbiome-immune axis, which is both a contributor to inflammation and a potential target for anti-inflammatory therapeutic strategies.

The young cohort enrolled for this study exhibits a markedly increased risk for cardiovascular disease, indicated by a high prevalence of arterial hypertension despite antihypertensive treatment as well as clear evidence of systemic inflammation (TNF- α). Inflammation is considered to be a main driver of cardiovascular disease in CKD¹⁵. Early cardiovascular pathologies and complications in children with CKD have been described previously^{16,17}, the burden of which accumulates with age and causes a fatal increase of CKD-associated mortality¹. This is remarkable given that CKD occurs in children in the virtual absence of diseases that can cause both CKD and CVD, such as diabetes and metabolic syndrome. This is particularly relevant for the present study, as traditional comorbidities in adults represent additional influences on microbiota-immune interaction. Therefore, it can be assumed that the microbiome and immune signatures presented here are influenced to a smaller degree by traditional comorbidities and represent specific signatures of CKD.

For the first time, we demonstrate that children with CKD already exhibit considerable stage-dependent intestinal barrier dysfunction indicated by increased serum levels of Zo-1 and sCD14. Zo-1 regulates intestinal permeability¹⁸ and has been associated with impaired barrier function in various conditions such as obesity, diabetes¹⁹ and autoimmune diseases²⁰. Impaired barrier function permits the translocation of luminal LPS into the circulation. Consequently, we detected a CKD stage dependent increase in serum levels of the LPS

binding protein sCD14, suggesting LPS-induced inflammation²¹⁻²³. Elevated serum levels of sCD14 have been associated with an increased risk of CVD in two independent cohort studies^{24,25}. Intestinal barrier dysfunction develops along with or as a consequence of dysbiosis, presumably as a consequence of a dysbalance of microbial metabolites, such as SCFA^{26,27}. Therefore, we analyzed the composition of the gut microbiome in our cohort. In line with studies of adult CKD patients^{5,7,28,29}, we observed CKD stage-dependent compositional changes. This microbial signature was most dominantly present in patients with HD displaying an increase of proteolytic bacteria such as *Citrobacter* (Enterobacteriaceae) and a decrease of saccharolytic bacteria such as *Bifidobacterium* (Bifidobacteriaceae), *Fusicatenibacter* (Lachnospiraceae) and *Subdoligranulum* (Ruminococcaceae). Since adults, unlike children, may well exhibit a variety of comorbidities whose presence can have an additional obscuring influence on the microbiome (e.g. diabetes³⁰, obesity³¹, and fatty liver disease³²), it can be assumed that the data presented here are less influenced by such comorbidities and therefore appear to be more clearly CKD-associated.

The enrichment of Enterobacteriaceae found in HD patients affects the microbial metabolism of nutrients as they express tryptophanases that metabolize TRP to indoles²⁹. Dietary TRP is metabolized both by somatic cells and by the intestinal microbiota to metabolites with various functions^{33,34}. We found that TRP metabolites in the blood of CKD patients increased in a stage-dependent manner, which was predominantly driven by the disproportional increase of metabolites of bacterial origin. Therefore, dysbiosis and intestinal barrier dysfunction, as present in CKD and HD patients in our cohort, are likely contributing to the accumulation of uremic solutes³⁵ in addition to their reduced renal elimination^{29,36}.

In our cohort, microbially-derived IxS and ILA as well as host-derived KYN, 3HK, KA, XA and AA were significantly elevated in CKD and HD patients, while serum levels of TRP were reduced. Both indole and KYN derivatives are ligands of the AhR, thereby influencing innate and adaptive immune responses^{10,33,34}. Consequently, the AhR activation potential of serum

from our HD patients was increased, confirming previous findings in adults³⁷. Of note, the degradation of TRP to KYN metabolites is regulated by tryptophan 2,3-dioxygenase in the liver, which is upregulated by chronic inflammation³⁸ and influenced by diabetes³⁹⁻⁴¹ and obesity⁴². In contrast to previous studies³⁹⁻⁴¹, our study emphasizes enhanced TRP metabolism and AhR activation in CKD irrespective of traditional comorbidities.

Myeloid cells are known to be modulated by the AhR and are thus particularly affected by uremic TRP metabolites^{10,33,34}. As indicated by unsupervised clustering and confirmed by hierarchical gating we demonstrated a pathological shift from classical towards intermediate and non-classical monocytes in HD patients. This monocyte signature has previously been associated with an increased risk of CVD^{43,44}. Most notably, we showed that isolated monocytes exhibited a higher production of TNF- α after incubation with serum from patients treated by HD compared to HC, which was dependent on AhR function. Thus, the increased TNF- α concentrations in the circulation are at least partly a consequence of the effect of the increased and mainly microbially produced TRP metabolites on the AhR of monocytes, and possibly also other immune cells.

In line with the depletion of SCFA-generating saccharolytic bacteria⁴⁵, such as *Bifidobacterium*, *Fusicatenibacter* and *Subdoligranulum* in CKD and HD patients, we show lower systemic levels of the SCFA propionate. There is a growing body of evidence about the pivotal role of SCFA in local gut homeostasis and the protection from CVD *in vitro*⁴⁶ and *in vivo*⁴⁷. Since SCFA are known to enhance the abundance and suppressive function of Treg cells in mice⁴⁸ and humans⁴⁹, we analyzed T cells by multi-color flow cytometry. Based on the expression of chemokine receptors^{14,50}, we found a decrease of Th1-like, Th17-like and Th22-like Treg in HD patients. The lower frequencies of these Treg subtypes might be explained by both, lower peripheral induction as a consequence of reduced availability of SCFA⁴⁸ and increased recruitment of Treg to sites of inflammation, e.g. atherosclerotic plaques⁵¹. Moreover, the frequency of dysfunctional Treg with a central memory phenotype expressing PD-1 was elevated in HD patients. Circulating Treg expressing PD-1 are known

to exhibit reduced suppressive function and molecular signatures of exhaustion⁵². In light of the recognized importance of chronic inflammation for CVD development, the diminished anti-inflammatory function as a consequence of reduced abundances of Treg subtypes and increased abundances of dysfunctional, exhausted Treg is likely to play a role in CVD development^{50,51}.

Interestingly, our unsupervised FlowSOM analysis clearly indicated that circulating MAIT cells were reduced in HD patients, expressed markers of exhaustion (PD-1) and produced higher amounts of IL-17A. This pattern has been described for several autoimmune, inflammatory and cardiometabolic diseases⁵³, such as obesity and type two diabetes⁵⁴. It is still a subject of discussion whether decreased MAIT cell abundances are mainly a consequence of migration to inflamed tissue or increased apoptosis⁵³. In animal models, MAIT cells can promote inflammation and microbial dysbiosis leading to metabolic dysfunction during obesity⁵³. A large cross-sectional analysis in patients with cardiometabolic diseases highlighted the positive association between decreased MAIT cell abundances and cardiovascular disease risk⁵⁵. A reduction of MAIT cell abundance has been described in CKD of predominantly diabetic cause, albeit without functional cytokine expression as shown here⁵⁶. Taken together, Treg and MAIT are two important cell populations phenotypically altered in HD patients that are known to be regulated by the microbiota, further emphasizing the importance of the microbiota-immune axis in CKD.

Noteworthy, patients after KT still showed significantly elevated serum levels of TNF- α compared to HC, albeit lower than in CKD and HD. There were no differences in serum markers of intestinal barrier function and only slight alterations in the microbiota composition, although the limited size of our cohort is less suited to detect fine-scaled differences between HC and KT. While microbial SCFA and indole metabolism apparently recovers after KT, serum levels of KYN and 3HK were still elevated. In contrast, adult patients after KT exhibited a significant decrease in alpha diversity and an increase of Proteobacteria, which is in part driven by the use of immunosuppressive drugs⁵⁷. In a murine kidney transplantation

model, mice after allograft transplantation exhibited dysbiosis even in the absence of antibiotics and immunosuppression⁵⁸. As gut dysbiosis and impaired microbial production of SCFA seem to play a role in allograft rejection as well⁵⁸, the absence of dysbiosis in children after KT might attribute to a more favorable transplant outcome in children compared to adults.

In conclusion, the present study is the first to show CKD stage-dependent alterations of the microbiota-metabolite-immune axis in children with CKD in the absence of comorbidities seen in adult patients. Our data demonstrate alterations at all levels of this pivotal axis. In this context, TRP metabolites act as a mechanistic link between the microbiota and the immune system, contributing to a pro-inflammatory phenotype in an AhR-dependent manner - even at a young age. SCFA deficiency may further exacerbate CKD-associated chronic inflammation and intestinal barrier dysfunction. These data provide strong evidence that the microbiota is an important stimulus for persistent inflammation. Restoring intestinal eubiosis could favorably influence the pro-inflammatory sequelae. Therefore, the microbiota appears a promising target of future therapeutic strategies aimed at sustained containment of inflammation to prevent chronic sequelae such as CVD and premature mortality in CKD.

Acknowledgments

This work was supported by local resources of the participating institutions. JH was supported by the Peter-Stiftung für die Nierenwissenschaft. JH, MW, SKF, and UL were supported by the German Center for Cardiovascular Research (DZHK), partner site Berlin. UL was supported by the German Federal Ministry of Education and Research (EMBARC; 01KI1909B) under the frame of JPI AMR (EMBARC; JPIAMR2019-109). S.G. was supported by the Bundesministerium für Bildung und Forschung funding MSTARs (Multimodal Clinical Mass Spectrometry to Target Treatment Resistance). F.B. was supported by the Berlin Institute of Health BIH-MD-TRENAL stipend. NW was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (852796) and by a grant from the Corona-Stiftung in the German Stifterverband. NW and SKF were supported by the Deutsche Forschungsgemeinschaft (German Research Foundation, SFB 1365 and SFB 1470). The sponsors had no involvement in study design, data collection, analysis and interpretation of data and in the decision to submit this article for publication.

The authors thank Gudrun Koch, Jana Czychi, Gabriele N'diaye and Kerstin Sommer for their technical assistance and Nadine Unterwalder for her kind support in analyzing serum cytokine levels.

Author contributions

J.H., N.W. and D.M. led and conceived the project. J.H. and H.B. designed and performed most experiments, analyzed and interpreted the data. J.H., S.K., D.E. and L.D.K. conducted patient recruitment under supervision of D.M.. U.L., T.U.P.B., H.A. and S.K.F. performed the statistical analyses and data integration. J.H., H.B., M.I.W. and A.M. performed and analyzed flow cytometry. V.M.P. performed most of the *in vitro* experiments. A.T. and O.D. performed 16S sequencing. D.L.V., M.K., S.G., S.K. and J.A.K. performed metabolite analysis. P.B.,

423 K.U.E., N.W., and D.M. helped with data interpretation. N.W. supervised the experiments and
424 data analysis. J.H., H.B. and N.W. wrote the manuscript with key editing by F.B., U.Q. and
425 K.U.E. and further input from all authors.

426

427 **Competing interest:** None declared.

428

429 **Data availability**

430 All data produced in the present study are available upon reasonable request to the authors.

431 Figures

Figure 1: Arterial hypertension and systemic inflammation are linked to impaired intestinal barrier function in pediatric chronic kidney disease. The number of antihypertensive drugs per individual (a, n= 48 patients) is shown in patients with chronic kidney disease (CKD G3-4), hemodialysis (HD), after kidney transplantation (KT) and healthy controls (HC). Plasma TNF-α (b, n=46 patients) was analyzed by chemiluminescence immunoassay. Gut barrier function was assessed using Zonulin 1 and soluble CD14 (c, n=40 patients) ELISA measurements in plasma. Data is shown as a box (median and interquartile range) and whiskers (min-max) with overlaid dot plot. *P* values ≤ 0.05 are shown, as measured by ordinary one-way ANOVA or Kruskal-Wallis test followed by Tukey's or Dunn's post-hoc correction for multiple comparisons, as appropriate.

Figure 2: Characteristics of gut microbiota in a cohort of pediatric patients with chronic kidney disease compared to healthy controls. Analysis of gut microbiota from 16S rRNA sequencing in children (n = 32) with chronic kidney disease (CKD G3-4), patients with hemodialysis (HD), patients after kidney transplantation (KT) and healthy controls (HC). a) Relative abundance on phylum level of individuals according to their respective group. b) Alpha diversity as measured by Shannon diversity. Data is shown as a box (median and interquartile range) and whiskers (min-max) with overlaid dot plot. c) Beta diversity assessment by Principal Coordinate Analysis (PCoA) based on Canberra distance (p = 0.01 by PERMANOVA). d) Analyses of group differences on genus level are shown as a heatmap. Patient groups were tested against each other (pairwise). The heatmap shows significant

455 changes in abundance using DESeq2 v1.30.1 package. Multiple groups of the same genus
 456 reported by Lotus due to lacking coverage in available phylogenetic databases are marked
 457 by numbers. Bar charts (right) show abundance and prevalence; abundance is calculated as
 458 $\log(\text{genus count})/\log(\max(\text{genus count}))$; prevalence for each genus is calculated across the
 459 whole data set. All significance estimates were adjusted for multiple tests using Benjamini-
 460 Hochberg FDR correction.

Figure 3: Stage-dependent activation of plasma tryptophan metabolism activates the Aryl-hydrocarbon receptor. Tryptophan (TRP) and its metabolites were measured in plasma of children at different stages of chronic kidney disease (CKD) compared to healthy controls (n = 48). a) Multivariate analysis (Principal Coordinate Analysis) of all measured metabolites discriminates between patients with CKD G3-4, patients with hemodialysis (HD), patients after kidney transplantation (KT) and healthy controls (HC). b) Cumulative load of TRP and its metabolites. c) Univariate analysis depicted as heatmap shows effect sizes (Cliff's delta) for each pair of patient groups. Colours denote the effect directions (blue-positive and red-negative) and magnitudes (the darker the colour, the stronger the magnitude); asterisks represent the association significance. Statistical significance was assessed by Mann-Whitney U-test and Benjamini-Hochberg false discovery rate correction.

Group differences of TRP (d), indoxyl sulfate (IxS, e) and kynurenin acid (KA, f) were further visualized in box plots. The Kynurenine/Tryptophan ratio (g) indicates the activity of tryptophan degradation to kynurenine metabolites. The activity of the Aryl-hydrocarbon receptor (AhR, h) was analyzed using a transfected reporter cell line after 48 hrs incubation with serum of HC (n=7) and HD (n=10) patients. *P* values ≤ 0.05 are shown, as measured by ordinary one-way ANOVA or Kruskal-Wallis test and adjusted by post-hoc Tukey's or Dunn's correction for multiple testing (d-g) or by t test (h). Data is shown as a box (median and interquartile range) and whiskers (min-max) with overlaid dot plot.

Abbreviations: TRP= tryptophan, 5OH-TRP= 5-hydroxy-tryptophan, TRYP= tryptamin, KYN= kynurenine, 3OH-KYN= 3-hydroxy-kynurenine, KA= kynurenic acid, AA= anthranilic acid, XA= xanthurenic acid, IxS= indoxyl sulfate; I3CA= indole-3-carboxyaldehyde, I3PA= indole-3-propionic acid, ILA= indole lactate, AhR= aryl hydrocarbon receptor.

Figure 4: Correlation network of gut microbiome, clinical parameters, plasma tryptophan metabolites and cytokines. Laboratory parameters, tryptophan metabolites (n = 48), cytokines (n=46) and taxonomic data (n = 32) were associated using pairwise Spearman correlations and adjusted for multiple testing using the Benjamini-Hochberg FDR correction. Edges for which absolute rho > 0.3 and Q < 0.1 are visualized. For better visualization eGFR was removed as creatinine and urea convey similar information. a) Positive correlations. b) Negative correlations.

Abbreviations: TRYP= tryptamin, TRP= tryptophan, KYN= kynurenine, KA= kynurenic acid, 3OH-KYN= 3-hydroxy-kynurenine, AA= anthranilic acid, XA= xanthurenic acid, PA= propionic acid, BA= butyric acid, Iso-Ba= isobutyric acid, Zo-1= zonulin-1, sCD14= soluble CD14, IxS= indoxyl sulfate, ILA= indole lactate, I3CA= indole-3-carboxyaldehyde, I3PA= indole-3-propionic acid, CrP= C-reactive protein. Crea= creatinine, phos= phosphate, Alb= albumin.

Figure 5: Monocyte subtypes promote inflammation in chronic kidney disease.

Monocytes isolated from healthy donors were incubated with serum from hemodialysis patients (HD, n=7) and healthy controls (HC, n=7). Monocytes were incubated with indoxyl sulfate (IxS) in presence or absence of the AhR antagonist CH-223191. TNF-α was measured in the culture supernatant after 24 hrs incubation using ELISA (a). Peripheral blood mononuclear cells (PBMC) were isolated from HD (n=6) and HC (n=7) individuals for surface staining and multi-color flow cytometry was performed. Unsupervised clustering by FlowSOM revealed 8 different cell clusters (b) characterized by the differential expression of 9 surface marker describing myeloid and dendritic cells (c). Cuneiform plots depict the log2-fold changes for these clusters between HD and HC (indicated by color, size and directionality of the triangles, d). Classical hierarchical gating of total monocytes, classical

510 monocytes (CD16+), non-classical (CD14+), and intermediate (CD14+CD16+) monocytes is
511 shown in e).

512 Abbreviations: AhR= aryl hydrocarbon receptor.

Figure 6: Pro-inflammatory T cell subtypes in chronic kidney disease. Unsupervised clustering of HD (n=6) and HC (n=7) individuals by FlowSOM revealed 8 T cell clusters (a) based on the differential expression of surface marker (b). c) Cuneiform plots showing the log2-fold changes for these clusters between HD and HC (indicated by color, size and directionality of the triangles). Volcano plot of MAIT (d) and Treg (e) subpopulations by hierarchical gating. y-axis indicates Q value by Mann-Whitney U-test and Benjamini-

520 Hochberg false discovery rate correction, x-axis log₂-fold change between HD and HC.
 521 Significantly altered subpopulations are depicted as box (median and interquartile range) and
 522 whiskers (min-max) with overlaid dot plots for MAIT and Treg in f) and g), respectively. For f
 523 and g, *P* values ≤ 0.05 are shown, as measured by t test or Mann-Whitney-U test as
 524 appropriate.

525 Abbreviations: MAIT= mucosa-associated invariant T cells; Treg= regulatory T cells, HD=
 526 hemodialysis, HC= healthy controls.

527 Tables

528 **Table 1: Patients baseline characteristics.** Patients (n = 48) were grouped into four
529 categories (CKD = chronic kidney disease, HD = hemodialysis, KT = kidney transplantation,
530 HC = healthy controls). Data is shown as mean $\pm$ standard deviation or percentage (%) as
531 appropriate.

Patients (n)	HC 10	CKD G3-G4 12	HD 11	KT 15
Age (years)	12.1 $\pm$ 4.2	8.3 $\pm$ 2.3	13.6 $\pm$ 3.2	9.1 $\pm$ 2.9
Female	7 (70%)	5 (42%)	3 (27%)	6 (40%)
Diagnosis				
CAKUT	N/A	5 (42%)	5 (45%)	8 (53%)
Tubulointerstitial	N/A	2 (17%)	1 (9%)	3 (20%)
Glomerulopathy	N/A	4 (33%)	4 (36%)	3 (20%)
Post-AKI	N/A	1 (8%)	1 (9%)	1 (7%)
Healthy	10 (100%)	N/A	N/A	N/A
Caucasian	9 (90%)	12 (100%)	3 (27%)	11 (73%)
Weight (percentile)	61 $\pm$ 23	38 $\pm$ 21	8 $\pm$ 7	52 $\pm$ 28
BMI (percentile)	57 $\pm$ 21	35 $\pm$ 19	31 $\pm$ 19	59 $\pm$ 25
eGFR (ml/min/1.73 m ²)	100.2 $\pm$ 29.3	29.6 $\pm$ 14.6	6.6 $\pm$ 1.1	78.6 $\pm$ 19.4
Urea (mg/dl)	30 $\pm$ 7	112 $\pm$ 67	147 $\pm$ 39	36 $\pm$ 14
Uric acid (mg/dl)	4.8 $\pm$ 1.3	7.6 $\pm$ 2.2	6.7 $\pm$ 1.2	5.4 $\pm$ 1.4
Phosphate (mmol/l)	1.3 $\pm$ 0.1	1.6 $\pm$ 0.3	2.0 $\pm$ 0.5	1.5 $\pm$ 0.3
Albumin (g/l)	47.7 $\pm$ 5.3	43.8 $\pm$ 13.0	38.0 $\pm$ 4.8	40.0 $\pm$ 3.4
CrP (mg/l)	2.6 $\pm$ 5.9	0.7 $\pm$ 1.1	3.6 $\pm$ 6.9	2.0 $\pm$ 1.8
PTH (pmol/l)	N/A	13.2 $\pm$ 8.5	38.5 $\pm$ 38.4	7.7 $\pm$ 3.8
Triglycerides (mg/dl)	N/A	166 $\pm$ 75	186 $\pm$ 54	112 $\pm$ 57
Antihypertensive treatment	0 (0%)	10 (83%)	10 (91%)	8 (53%)
Antihypertensive drugs (n)	0	1.8 $\pm$ 1.5	2.4 $\pm$ 1.9	0.8 $\pm$ 0.9
Arterial Hypertension (BP > 95 th Percentile)	N/A	2 (17%)	6 (55%)	5 (33%)

532 Abbreviations: CAKUT = congenital anomalies of the kidney and urinary tract; Post-AKI =
533 patients with chronic kidney disease after acute kidney injury; BP = blood pressure; N/A = not
534 applicable.

References

- 1 Gansevoort, R. T. *et al.* Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* **382**, 339-352, doi:10.1016/S0140-6736(13)60595-4 (2013).
- 2 Claro, L. M. *et al.* The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease. *Toxins (Basel)* **10**, doi:10.3390/toxins10100384 (2018).
- 3 Onal, E. M., Afsar, B., Covic, A., Vaziri, N. D. & Kanbay, M. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. *Hypertens Res* **42**, 123-140, doi:10.1038/s41440-018-0144-z (2019).
- 4 Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc Nephrol* **25**, 1897-1907, doi:10.1681/ASN.2013101062 (2014).
- 5 Vaziri, N. D. *et al.* Chronic kidney disease alters intestinal microbial flora. *Kidney Int* **83**, 308-315, doi:10.1038/ki.2012.345 (2013).
- 6 Ramezani, A. *et al.* Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. *Am J Kidney Dis* **67**, 483-498, doi:10.1053/j.ajkd.2015.09.027 (2016).
- 7 Wang, X. *et al.* Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. *Gut* **69**, 2131-2142, doi:10.1136/gutjnl-2019-319766 (2020).
- 8 Holle, J. *et al.* Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. *Pediatr Nephrol*, doi:10.1007/s00467-019-04331-6 (2019).
- 9 Harambat, J., van Stralen, K. J., Kim, J. J. & Tizard, E. J. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol* **27**, 363-373, doi:10.1007/s00467-011-1939-1 (2012).
- 10 Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. *Nat Rev Immunol* **19**, 184-197, doi:10.1038/s41577-019-0125-8 (2019).
- 11 Quintelier, K. *et al.* Analyzing high-dimensional cytometry data using FlowSOM. *Nat Protoc* **16**, 3775-3801, doi:10.1038/s41596-021-00550-0 (2021).
- 12 Abeles, R. D. *et al.* CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure. *Cytometry A* **81**, 823-834, doi:10.1002/cyto.a.22104 (2012).
- 13 Wong, K. L. *et al.* Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. *Blood* **118**, e16-31, doi:10.1182/blood-2010-12-326355 (2011).
- 14 Duhon, T., Duhon, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. *Blood* **119**, 4430-4440, doi:10.1182/blood-2011-11-392324 (2012).
- 15 Jankowski, J., Floege, J., Fliser, D., Bohm, M. & Marx, N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation* **143**, 1157-1172, doi:10.1161/CIRCULATIONAHA.120.050686 (2021).
- 16 Mitsnefes, M. M. Cardiovascular disease in children with chronic kidney disease. *J Am Soc Nephrol* **23**, 578-585, doi:10.1681/ASN.2011111115 (2012).
- 17 Schaefer, F. *et al.* Cardiovascular Phenotypes in Children with CKD: The 4C Study. *Clin J Am Soc Nephrol* **12**, 19-28, doi:10.2215/CJN.01090216 (2017).
- 18 Fasano, A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. *Physiol Rev* **91**, 151-175, doi:10.1152/physrev.00003.2008 (2011).
- 19 Yuan, J. H. *et al.* Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP. *J Diabetes Complications* **35**, 107766, doi:10.1016/j.jdiacomp.2020.107766 (2021).

586 20 Tajik, N. *et al.* Targeting zonulin and intestinal epithelial barrier function to prevent onset of
587 arthritis. *Nat Commun* **11**, 1995, doi:10.1038/s41467-020-15831-7 (2020).

588 21 Schutt, C., Schilling, T., Grunwald, U., Schonfeld, W. & Kruger, C. Endotoxin-neutralizing
589 capacity of soluble CD14. *Res Immunol* **143**, 71-78, doi:10.1016/0923-2494(92)80082-v
590 (1992).

591 22 Poesen, R. *et al.* Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular
592 Disease, and Progression of Kidney Disease among Patients with CKD. *Clin J Am Soc Nephrol*
593 **10**, 1525-1533, doi:10.2215/CJN.03100315 (2015).

594 23 Zanon, I. & Granucci, F. Role of CD14 in host protection against infections and in metabolism
595 regulation. *Front Cell Infect Microbiol* **3**, 32, doi:10.3389/fcimb.2013.00032 (2013).

596 24 Stanislawski, M. A. *et al.* Soluble CD14 Levels in the Jackson Heart Study: Associations With
597 Cardiovascular Disease Risk and Genetic Variants. *Arterioscler Thromb Vasc Biol* **41**, e369-
598 e378, doi:10.1161/ATVBAHA.121.316035 (2021).

599 25 Olson, N. C. *et al.* Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a
600 Prospective Study: The REGARDS Cohort. *J Am Heart Assoc* **9**, e014241,
601 doi:10.1161/JAHA.119.014241 (2020).

602 26 Hiippala, K. *et al.* The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function
603 and Alleviating Inflammation. *Nutrients* **10**, doi:10.3390/nu10080988 (2018).

604 27 Geirnaert, A. *et al.* Butyrate-producing bacteria supplemented in vitro to Crohn's disease
605 patient microbiota increased butyrate production and enhanced intestinal epithelial barrier
606 integrity. *Sci Rep* **7**, 11450, doi:10.1038/s41598-017-11734-8 (2017).

607 28 Hobby, G. P. *et al.* Chronic kidney disease and the gut microbiome. *Am J Physiol Renal Physiol*
608 **316**, F1211-F1217, doi:10.1152/ajprenal.00298.2018 (2019).

609 29 Gryp, T. *et al.* Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria
610 in Chronic Kidney Disease Patients. *Int J Mol Sci* **21**, doi:10.3390/ijms21061986 (2020).

611 30 Forslund, K. *et al.* Disentangling type 2 diabetes and metformin treatment signatures in the
612 human gut microbiota. *Nature* **528**, 262-266, doi:10.1038/nature15766 (2015).

613 31 Bouter, K. E., van Raalte, D. H., Groen, A. K. & Nieuwdorp, M. Role of the Gut Microbiome in
614 the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. *Gastroenterology*
615 **152**, 1671-1678, doi:10.1053/j.gastro.2016.12.048 (2017).

616 32 Chu, H., Williams, B. & Schnabl, B. Gut microbiota, fatty liver disease, and hepatocellular
617 carcinoma. *Liver Res* **2**, 43-51, doi:10.1016/j.livres.2017.11.005 (2018).

618 33 Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. *Nat*
619 *Commun* **9**, 3294, doi:10.1038/s41467-018-05470-4 (2018).

620 34 Dodd, D. *et al.* A gut bacterial pathway metabolizes aromatic amino acids into nine
621 circulating metabolites. *Nature* **551**, 648-652, doi:10.1038/nature24661 (2017).

622 35 Vaziri, N. D., Yuan, J. & Norris, K. Role of urea in intestinal barrier dysfunction and disruption
623 of epithelial tight junction in chronic kidney disease. *Am J Nephrol* **37**, 1-6,
624 doi:10.1159/000345969 (2013).

625 36 Poesen, R. *et al.* Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl
626 sulfate in CKD. *Clin J Am Soc Nephrol* **8**, 1508-1514, doi:10.2215/CJN.00300113 (2013).

627 37 Dou, L. *et al.* Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney
628 disease. *Kidney Int* **93**, 986-999, doi:10.1016/j.kint.2017.11.010 (2018).

629 38 Schefold, J. C. *et al.* Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum
630 levels of tryptophan catabolites in patients with chronic kidney disease: a possible link
631 between chronic inflammation and uremic symptoms. *Nephrol Dial Transplant* **24**, 1901-
632 1908, doi:10.1093/ndt/gfn739 (2009).

633 39 Mair, R. D., Sirich, T. L. & Meyer, T. W. Uremic Toxin Clearance and Cardiovascular Toxicities.
634 *Toxins (Basel)* **10**, doi:10.3390/toxins10060226 (2018).

635 40 Debnath, S. *et al.* Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary
636 to Type 2 Diabetes: Relationship to Inflammatory Markers. *Int J Tryptophan Res* **10**,
637 1178646917694600, doi:10.1177/1178646917694600 (2017).

638 41 Pawlak, K., Kowalewska, A., Mysliwiec, M. & Pawlak, D. Kynurenine and its metabolites--
639 kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion
640 molecules and oxidative status in patients with chronic kidney disease. *Am J Med Sci* **338**,
641 293-300, doi:10.1097/MAJ.0b013e3181aa30e6 (2009).

642 42 Cusotto, S. *et al.* Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated
643 With Systemic Inflammation. *Front Immunol* **11**, 557, doi:10.3389/fimmu.2020.00557 (2020).

644 43 Duni, A. *et al.* The Association of Circulating CD14++CD16+ Monocytes, Natural Killer Cells
645 and Regulatory T Cells Subpopulations With Phenotypes of Cardiovascular Disease in a
646 Cohort of Peritoneal Dialysis Patients. *Front Med (Lausanne)* **8**, 724316,
647 doi:10.3389/fmed.2021.724316 (2021).

648 44 Heine, G. H. *et al.* Monocyte subpopulations and cardiovascular risk in chronic kidney
649 disease. *Nat Rev Nephrol* **8**, 362-369, doi:10.1038/nrneph.2012.41 (2012).

650 45 Felizardo, R. J. F., Watanabe, I. K. M., Dardi, P., Rossoni, L. V. & Camara, N. O. S. The interplay
651 among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
652 *Pharmacol Res* **141**, 366-377, doi:10.1016/j.phrs.2019.01.019 (2019).

653 46 Bartolomaeus, H. *et al.* Short-Chain Fatty Acid Propionate Protects From Hypertensive
654 Cardiovascular Damage. *Circulation* **139**, 1407-1421,
655 doi:10.1161/CIRCULATIONAHA.118.036652 (2019).

656 47 Hsu, C. N., Lu, P. C., Hou, C. Y. & Tain, Y. L. Blood Pressure Abnormalities Associated with Gut
657 Microbiota-Derived Short Chain Fatty Acids in Children with Congenital Anomalies of the
658 Kidney and Urinary Tract. *J Clin Med* **8**, doi:10.3390/jcm8081090 (2019).

659 48 Arpaia, N. *et al.* Metabolites produced by commensal bacteria promote peripheral regulatory
660 T-cell generation. *Nature* **504**, 451-455, doi:10.1038/nature12726 (2013).

661 49 Haghighi, A. *et al.* Propionate attenuates atherosclerosis by immune-dependent regulation of
662 intestinal cholesterol metabolism. *Eur Heart J*, doi:10.1093/eurheartj/ehab644 (2021).

663 50 Halim, L. *et al.* An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like
664 Tregs that Support a Tumorigenic Environment. *Cell Rep* **20**, 757-770,
665 doi:10.1016/j.celrep.2017.06.079 (2017).

666 51 Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. *Nat Rev*
667 *Cardiol* **17**, 387-401, doi:10.1038/s41569-020-0352-5 (2020).

668 52 Lowther, D. E. *et al.* PD-1 marks dysfunctional regulatory T cells in malignant gliomas. *JCI*
669 *Insight* **1**, doi:10.1172/jci.insight.85935 (2016).

670 53 Toubal, A. *et al.* Mucosal-associated invariant T cells promote inflammation and intestinal
671 dysbiosis leading to metabolic dysfunction during obesity. *Nat Commun* **11**, 3755,
672 doi:10.1038/s41467-020-17307-0 (2020).

673 54 Magalhaes, I. *et al.* Mucosal-associated invariant T cell alterations in obese and type 2
674 diabetic patients. *J Clin Invest* **125**, 1752-1762, doi:10.1172/JCI78941 (2015).

675 55 Touch, S. *et al.* Mucosal-associated invariant T (MAIT) cells are depleted and prone to
676 apoptosis in cardiometabolic disorders. *FASEB J*, fj201800052RR,
677 doi:10.1096/fj.201800052RR (2018).

678 56 Juno, J. A. *et al.* Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered
679 Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating
680 Factor Production During End-Stage Renal Disease. *Front Immunol* **9**, 1076,
681 doi:10.3389/fimmu.2018.01076 (2018).

682 57 Swarte, J. C. *et al.* Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant
683 Recipients. *J Clin Med* **9**, doi:10.3390/jcm9020386 (2020).

684 58 Wu, H. *et al.* Gut Microbial Metabolites Induce Donor-Specific Tolerance of Kidney Allografts
685 through Induction of T Regulatory Cells by Short-Chain Fatty Acids. *J Am Soc Nephrol*,
686 doi:10.1681/ASN.2019080852 (2020).

687